Tedatioxetine
{{Drugbox | Verifiedfields = changed | Watchedfields = changed | verifiedrevid = 454958463 | IUPAC_name = 4-{2-[(4-methylphenyl)sulfanyl]phenyl}piperidine | image = Tedatioxetine.svg | width = 175 | image2 = File:Tedatioxetine ball-and-stick model.png | width2 = 250
| tradename = | pregnancy_category = | legal_status = Investigational | routes_of_administration =
| bioavailability = | metabolism = | elimination_half-life = | excretion =
| CAS_number_Ref = 
| CAS_number = 508233-95-2
| ATC_prefix = none
| ATC_suffix =
| KEGG = D10170
| KEGG_Ref = 
| synonyms = Lu AA24530; Lu-AA-24530
| C=18 | H=21 | N=1 | S=1
| molecular_weight = 283.43 g/mol
| smiles = CC(C=C1)=CC=C1SC2=C(C3CCNCC3)C=CC=C2
| PubChem = 9878913
| ChemSpiderID_Ref =
| ChemSpiderID = 8054590
| InChI = 1/C18H21NS/c1-14-6-8-16(9-7-14)20-18-5-3-2-4-17(18)15-10-12-19-13-11-15/h2-9,15,19H,10-13H2,1H3
| InChIKey = CVASBKDYSQKLSO-UHFFFAOYAT
| StdInChI_Ref =
| StdInChI = 1S/C18H21NS/c1-14-6-8-16(9-7-14)20-18-5-3-2-4-17(18)15-10-12-19-13-11-15/h2-9,15,19H,10-13H2,1H3
| StdInChIKey_Ref =
| StdInChIKey = CVASBKDYSQKLSO-UHFFFAOYSA-N
}}
Tedatioxetine (Lu AA24530) is an antidepressant that was discovered by scientists at Lundbeck; in 2007 Lundbeck and Takeda entered into a partnership that included tedatioxetine but was focused on another, more advanced Lundbeck drug candidate, vortioxetine.[1]
Tedatioxetine is reported to act as a triple reuptake inhibitor (5-HT > NE > DA) and 5-HT2A, 5-HT2C, 5-HT3 and α1A-adrenergic receptor antagonist.[2][3][4][5]
As of 2009, it was in phase II clinical trials for major depressive disorder,[5] but there have been no updates since then, and as of August 2013 it was no longer displayed on Lundbeck's product pipeline.[6][7]
See also
References
- ^ Daniel Beaulieu for First Word Pharma. September 5th, 2007 Lundbeck, Takeda enter strategic alliance for mood disorder, anxiety drugs
- ^ "Patent US20100144788 - 4- [2- (4-methylphenylsulfanyd-phenyl] piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of adhd, melancholia, treatment resistant depression or residual symptoms in depression". Retrieved 7 April 2014.
- ^ Stephen M. Stahl (19 May 2008). Depression and bipolar disorder: Stahl's essential psychopharmacology. Cambridge University Press. p. 206. ISBN 978-0-521-88663-5. Retrieved 22 November 2011.
- ^ Ian P. Stolerman (30 August 2010). Encyclopedia of Psychopharmacology. Springer. p. 105. ISBN 978-3-540-68698-9. Retrieved 22 November 2011.
- ^ a b "Lu AA24530 shows positive results in major depressive disorder phase II study - FierceBiotech".
- ^ "Pipeline of Lundbeck". Retrieved 25 August 2013.
- ^ UK Medicines Information Tedatioxetine entry in UKMI. Page accessed January 20, 2016
External links
 | This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |